Skip to main content

Table 3 Overall survival (OS) and progression-free survival (PFS) for s-CPM and m-CPM patients post CRS and HIPEC

From: The importance of synchronicity in the management of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

 No. of events/no. of patientMedian OS, (95% CI)1 year rate, % (95% CI)3 year rate, % (95% CI)5 year rate,% (95% CI)p value
Overall survival
 s-CPM9/2026.9 (9.8–44.5)77.0 (43.2–92.2)27.5 (4.5–58.4)13.8 (0.8–44.7)0.025
 m-CPM25/8245.2 (30.2–54.3)92.1 (81.3–96.0)62.0 (45.1–74.6)31.2 (15.1–48.4) 
Progression-free survival
 s-CPM9/2019.7 (7.7–43.2)75.5 (41.6–91.4)28.8 (5.2–59.1)00.356
 m-CPM45/8230.2 (19.8–37.8)92.2 (82.3–96.7)39.8 (26.2–52.9)10.2 (3.5–21.5)